INTERACTIONS: WHAT YOU SHOULD KNOW Council on Family Health. Drug Interactions T here are more opportunities today than ever. What are possible drug interaction signs I should. Warfarin and its interactions with foods, herbs and other dietary supplements 434 Expert Opin. (2006) 5(3) 10-hydroxywarfarin and 4′-hydroxywarfarin (minor pathway). Warfarin has a narrow therapeutic index. A patient’s interna-tional normalised ratio (INR) should be monitored frequently to maintain values within the desired. An unexpected protein interaction promotes drug resistance in leukemia Aaron Pitre 1, Yubin Ge 2, Wenwei Lin 3, Yao Wang 1, Yu Fukuda 1, Jamshid Temirov 4, Aaron H. A food-drug interaction can prevent a medicine from working the way it should or can cause a side effect from a medicine to get worse or better. Besides, it can cause a new side effect [FDA 2013]. TYPES OF DRUG-NUTRIENT INTERACTIONS DNIs can be mechanistically called in pharma-ceutic, pharmacokinetic and pharmacodynamic terms (Fig. Etienne de crecy tempovision.
Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation. The main part of the book describes examples of protein targets for which small molecule modulators have been developed, covering such diverse fields as cancer, autoimmune disorders and infectious diseases. Tailor-made for the practicing medicinal chemist, this ready reference includes a wide selection of case studies taken straight from the development pipeline of major pharmaceutical companies to illustrate the power and potential of this approach.
From the contents:
* Prediction of intra- and inter-species protein-protein interactions facilitating systems biology studies
* Modulators of protein-protein interactions: The importance of Three-Dimensionality
* Interactive technologies for leveraging the known chemistry of anchor residues
Protein Interaction Network
* SH3 Domains as Drug Targets
* P53 MDM2 Antagonists: Towards Non Genotoxic Anticancer Treatments
* Inhibition of LFA-1/ICAM interaction for treatment of autoimmune diseases
* The PIF-binding pocket of AGC kinases
* Peptidic inhibitors of protein-protein interactions for cell adhesion receptors
* The REPLACE Strategy for generating Non-ATP competitive Inhibitors of Cell-Cycle Protein Kinases
and more
- Issued by:
This guidance helps sponsors of investigational new drug applications and applicants of new drug applications evaluate drug-drug interactions (DDIs) during drug development and communicate the results and recommendations from DDI studies.
Submit Comments
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Food Drug Interactions Chart
Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852
Drug Protein Interaction Database
All comments should be identified with the title of the guidance.